Founded in 2022, Theta Neurotech is developing the first wearable seizure prediction system: a discreet EEG patch paired with an AI-powered companion app.

Our scientific advisors come from the University of Chicago, the University of Virginia, and UC San Francisco. We are preparing for clinical trials and recently closed our pre-seed funding round.

The company's core technology enables 24/7 ambulatory EEG capture in a form factor designed for everyday life, paired with a proprietary AI engine that translates neural signals into actionable predictions. Our long-term vision extends beyond epilepsy. We see a future where continuous brain monitoring is as routine as heart rate tracking.

“Theta's mission is personal. We are building this technology because the epilepsy community has waited too long for a prediction tool that works outside the hospital.”
— Truman Pierson, Founder, CEO

  • Truman Pierson

    FOUNDER, CEO
    University of Chicago

  • Christopher Fitz

    FOUNDER, CTO
    Vanderbilt University

  • Naoum Issa, MD, PhD

    PRINCIPAL INVESTIGATOR
    University of Chicago Medicine

    Section Chief of Epilepsy and Director of Epilepsy Research at the University of Chicago. Dr. Issa's research focuses on detecting and diagnosing neurologic disorders using non-invasive electrophysiological techniques. He has published over 75 scientific papers.

  • Nathan Fountain, MD

    SCIENTIFIC ADVISOR
    University of Virginia

    Thomas E. Worrell, Jr. Professor of Neurology and Epileptology and Director of the F.E. Dreifuss Comprehensive Epilepsy Program at UVA. Former chair of the FDA Advisory Committee for neurology drugs and past president of the National Association of Epilepsy Centers.

  • Vikram Rao, MD, PhD

    SCIENTIFIC ADVISOR
    UC San Francisco

    Distinguished Professor of Neurology at UCSF and member of the Weill Institute for Neurosciences. Dr. Rao's research uses chronic brain recordings and implanted neurostimulation devices to forecast seizures, including a Nature Medicine publication demonstrating that hippocampal network activity can predict 24-hour seizure risk.

Research & Clinical Partners